Related Experiment Video
Updated: Dec 10, 2025
09:56
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
1.1K
Second primary malignancy after rituximab-containing immunochemotherapy for diffuse large B cell lymphoma
Yoshiaki Chinen1,2, Kazuna Tanba1, Ryo Takagi3
1Department of Hematology, Fukuchiyama City Hospital, Fukuchiyama, Japan.
Leukemia & Lymphoma
|August 28, 2020
Summary
Long-term survival in diffuse large B cell lymphoma (DLBCL) patients may increase late adverse events, including second primary malignancies (SPMs). This study found SPM risk increases over time, regardless of prior cancer history, highlighting the need for vigilance.
Area of Science:
- Oncology
- Hematology
Background:
- Long-term survival in diffuse large B cell lymphoma (DLBCL) patients treated with immunochemotherapy is increasing.
- This improved survival may be associated with a higher incidence of late adverse events, such as second primary malignancies (SPMs).
Purpose of the Study:
- To investigate the frequency and clinical characteristics of SPMs in DLBCL patients treated with rituximab-containing immunochemotherapy.
- To assess the influence of past or synchronous cancer history on SPM development.
Main Methods:
- Retrospective analysis of 809 DLBCL patients treated at seven institutes.
- Median follow-up of 899 days.
- Analysis of SPM incidence and types, stratified by prior cancer history.
Main Results:
- 69 SPMs were observed in 58 patients (7.2%) over the follow-up period.
- The most common SPMs were gastric, lung, and colorectal cancers.
- The cumulative incidence of SPM increased steadily over time and was not significantly affected by prior cancer history.
Conclusions:
- Patients with DLBCL treated with rituximab-containing immunochemotherapy have a notable risk of developing SPMs.
- Vigilance for SPM development is crucial in the long-term management of DLBCL survivors.
- Prior cancer history did not significantly alter the risk of developing subsequent primary malignancies.
Related Concept Videos
01:15Secondary Lymphoid Organs
8.5K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
8.5K
01:16Primary Lymphoid Organs
14.3K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
14.3K
01:27Tumor Immunotherapy
1.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.5K
01:23Cells of the Adaptive Immune Response
8.2K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
8.2K
02:56Treatment Resistant Cancers
3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K